Showing results (21-30 of 41) with videos related to
Sort By:
Pageof 5
Journal of Cardiovascular Electrophysiology|October 14, 2025
Predictors of Permanent Pacemaker Implantation Following Valve-in-Valve Transcatheter Aortic Valve ReplacementKarol Quelal Analuisa, Namrata Arya, Teodora Donisan, et al.Rare Tumors|September 12, 2019
Extraskeletal osteosarcoma: A large series treated at a single institutionHaotong Wang, Ruoyu Miao, Alex Jacobson, et al.The Oncologist|February 25, 2012
Phase II study of sequential gemcitabine followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma: results of Sarcoma Alliance for Research Through Collaboration Study 003Elizabeth Fox, Shreyaskumar Patel, J Kyle Wathen, et al.Gynecologic Oncology|February 14, 2015
NSC23925 prevents the emergence of multidrug resistance in ovarian cancer in vitro and in vivoXiaoqian Yang, Yong Feng, Yan Gao, et al.Journal of Medicinal Chemistry|March 10, 2012
Synthesis and evaluation of (2-(4-methoxyphenyl)-4-quinolinyl)(2-piperidinyl)methanol (NSC23925) isomers to reverse multidrug resistance in cancerZhenfeng Duan, Xin Li, Haoxi Huang, et al.Journal of Orthopaedic Research : Official Publication of the Orthopaedic Research Society|January 22, 2016
Evaluation of P-glycoprotein (Pgp) expression in human osteosarcoma by high-throughput tissue microarrayYan Gao, Yunfei Liao, Jacson K Shen, et al.Scientific Reports|August 11, 2018
Author Correction: Androgen receptor is a potential novel prognostic marker and oncogenic target in osteosarcoma with dependence on CDK11Yunfei Liao, Slim Sassi, Stefan Halvorsen, et al.Scientific Reports|March 7, 2017
Androgen receptor is a potential novel prognostic marker and oncogenic target in osteosarcoma with dependence on CDK11Yunfei Liao, Slim Sassi, Stefan Halvorsen, et al.British Journal of Pharmacology|November 26, 2015
NVP-TAE684 reverses multidrug resistance (MDR) in human osteosarcoma by inhibiting P-glycoprotein (PGP1) functionShunan Ye, Jianming Zhang, Jacson Shen, et al.BMC Cancer|September 20, 2014
A-770041 reverses paclitaxel and doxorubicin resistance in osteosarcoma cellsZhenfeng Duan, Jianming Zhang, Shunan Ye, et al.Pageof 5